Agomab Therapeutics AGMB
NASDAQ AGMB
$13.25 -0.18 (-1.34%)
At close: Aug 21, 2026 · 4:00 PM EDT

Agomab Therapeutics (AGMB) Prepaid Assets (2024 - 2025)

Agomab Therapeutics (AGMB) posted quarterly Prepaid Assets of $5.5 million for Q4 2025, up 115.63% year-over-year from $2.5 million in Q4 2024, and up 115.63% quarter-over-quarter from $2.5 million in Q4 2024.

Agomab Therapeutics (AGMB) Prepaid Assets (2024 - 2025) Analysis & Trends

Agomab Therapeutics' Prepaid Assets history runs 2 years deep, the most recent figure standing at $5.5 million for Q4 2025.

  • In Q4 2025, Prepaid Assets rose 115.63% year-over-year to $5.5 million; the TTM figure through Dec 2025 stood at $5.5 million (up 115.63% YoY), while the FY2025 annual figure was $5.5 million, up 112.89% from the prior year.
  • Prepaid Assets for Q4 2025 stood at $5.5 million, up from $2.5 million in the prior quarter.
  • The five-year high for Prepaid Assets was $5.5 million in Q4 2025, with the low at $2.5 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Agomab Therapeutics 7.07 Mn -250.51 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 5.50 Mn
Dec 31, 2024 2.55 Mn